Release data update for anti-PD1 failed non-melanoma skin cancers

Delivered after the deadline

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced: 3 Nov 2022
Due: 30 Jun 2023
Delivered: December 2023

Deadline
Met
Late
Not met
Today

What the company said

“Recruitment remains ongoing into the cohorts of patients with anti-PD1 failed non-melanoma skin cancers, including CSCC with a data update expected in H1 2023.”

SourceReplimune Group, Inc. Form 8-K press release, 2022-11-03
FilingSEC filing index
Deadline as statedH1 2023
Deadline used30 Jun 2023, the last day of the stated period
TypeProduct
Permanent referenceKI-C-2022-REPL-002693
Cite as https://keptindex.org/c/KI-C-2022-REPL-002693/ — this address never changes.

What we found

Evidence strength A What the grades mean

The company missed its H1 2023 deadline for the data update, pushing the expectation to Q4 2023 and ultimately delivering the update in December 2023.

A
Replimune Group, Inc. 8-K filed 2023-08-03 Regulatory filing · published 3 Aug 2023 · retrieved 1 Oct 2026 · kept permanently by the SEC
“Recruitment remains ongoing into the cohort of patients with anti-PD1 failed non-melanoma skin cancers, including CSCC, with a data update expected from the first 30 patients with at least six months follow up in early Q4 2023.” ✓ confirmed on the page
A
Replimune Group, Inc. 10-Q filed 2024-02-08 Regulatory filing · published 8 Feb 2024 · retrieved 1 Oct 2026 · kept permanently by the SEC
“In our non-melanoma skin cancer, or NMSC, cohort of the IGNYTE clinical trial, we provided a data update in December 2023” ✓ confirmed on the page

Market reaction: the shares moved -11.2% against the S&P 500 over the three sessions around the disclosure (2 Aug 2023 to 7 Aug 2023). What this measures

Checked 1 Oct 2026.

Commitment lineage

Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.

Deadline drift +92 days
2 versions

Version 1 · original · stated 3 Nov 2022

Deadline 30 Jun 2023 (“H1 2023”) · wording expected
Version 2 · stated 18 May 2023

Deadline 30 Sep 2023 (“Q3 2023”) · wording expected

“Recruitment remains ongoing into the cohort of patients with anti-PD1 failed non-melanoma skin cancers, including CSCC, with a data update expected in Q3 2023.”
Source for this version

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Commercial launch
Indicative materiality: Medium rules
Action: Release
Deliverable: Anti-PD1 failed non-melanoma skin cancers data update
Language: Expected (“expects”, “plans”)
In the company’s control: High
Specificity: High

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you Replimune Group, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.